Tribune News Service
New Delhi, July 1
The government today said the Patanjali Trust could market its new tablet “Coronil” as an immunity booster, but not as a Covid therapy.
In a letter to the Uttarakhand Licensing Authority and the Patanjali Trust, the Ministry of Ayush said it examined the matter and found that Coronil had been registered with the state licensing authority as an immunity booster, while the two other formulations in the so-called Covid package were earlier registered as Ayurvedic drugs for “kasa and svasa”.
It said, “The proposed three drugs — Divya Coronil tablet, Divya Shwashari Vati 540mg and Divya Shwashari Vati 350 mg — should be marketed as per the scope of the licence issued by the Uttarakhand Licensing Authority, Ayurvedic and Unani Services. On the package and the label of these drugs, no claim about cure of Covid-19 should be mentioned.”
The ministry, however, said Patanjali had initiated clinical trials for potential Covid-19 therapy as per government guidelines and the trust could continue with those trials as per procedure.
A Bench headed by Justice Arun Mishra will hear arguments on...
Born to a Jamaican father and an Indian mother, 55-year-old ...
Death toll crosses 48,000